Skip to content

Author

Zhengqing Qiu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety, Efficacy, and Pharmacokinetics of Agalsidase Alfa in Treatment-Naive Chinese Patients with Fabry Disease: 52-Week Phase 3, Open-Label, Single-Arm Study.

Data from this 52-week study support the use of agalsidase alfa as a long-term treatment option for Chinese patients with Fabry disease and safety, efficacy, and pharmacokinetic profiles were consistent with studies in other populations.

Hong Ren, Jian-Hua Mao, Rong Wang et al. · 0 citations
Open access Aug 2026

Improving molecular diagnosis of fabry disease: functional validation of novel splicing variants in GLA

The findings highlight the critical role of robust functional splicing assays in interpreting variant pathogenicity, establishing accurate genotype-phenotype correlations, and ultimately facilitating precision medicine for FD.

Jingwen Zhou, Ai-Ping Mao, Jie Feng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.